Case Report

Clear Cell Carcinoma Arising in Vulvar Endometriosis

Pranom Buppasiri, Pilaiwan Kleebkaow, Chantip Tharanon, Apiwat Aue-aungkul, and Chumnan Kietpeerakool

Department of Obstetrics and Gynaecology, Faculty of Medicine, Khon Kaen University, Thailand

Correspondence should be addressed to Chumnan Kietpeerakool; kiet_ji@hotmail.com

Received 10 May 2018; Revised 1 July 2018; Accepted 19 July 2018; Published 26 July 2018

Abstract

Women with endometriosis have an increased risk of certain histologic types of cancer, which mostly involve the ovary [3]. In the recent model of epithelial ovarian carcinogenesis, endometriosis has been proposed as a precancerous lesion of endometrioid, clear cell, and seromucinous carcinomas of the ovary [4]. The malignant transformation of extrapelvic endometriosis is extremely rare [3]. Therefore, an accumulation of case reports regarding this uncommon clinical entity is necessary in order to verify its clinical course and predisposing factors. Herein, we present a rare case of a patient with clear cell carcinoma of the vulva related to neoplastic transformation of endometriosis who presented with a painful mass at the right side of the groin and labia major.

1. Introduction

Endometriosis is characterized by the presence of endometrial glands and stroma similar to that in the endometrial lining, but in a location outside of the uterine cavity [1]. Endometriosis can be further classified as either endopelvic or extrapelvic depending on the location of the endometrial tissue implantation [1]. Endopelvic endometriosis commonly involves the ovaries, fallopian tubes, uterosacral ligament, pouch of Douglas, and rectovaginal septum. Endometriosis deposits can also occur in the gastrointestinal tract, thoracic cage and lungs, diaphragm, nervous system, and mucocutaneous tissue [1]. A previous study found the prevalence of extrapelvic endometriosis to be 20% in women with endometriosis [2]. In that study, the gastrointestinal tract was the most common site of extrapelvic endometriosis (52%), followed by the urinary tract (35%). In addition, approximately 78% of women with extrapelvic endometriosis also had pelvic endometriosis [2].

2. Case Presentation

A 46-year-old nulliparous woman presented after having experienced pain in the right side of her groin and labia...
Figure 1: Microscopic examination of the labial mass reveals multiple foci of endometriosis (4x).

Figure 2: Microscopic examination shows a focus of endometriosis in the labial mass that lined by endometrial cells with cytologic atypia (10x).

majora for four months, as well as a lump that was increasing in size. She had previously undergone three laparotomies for ovarian cystectomy at 20, 10, and 8 years prior to this visit due to her severe progressive pelvic pain. The pathological examinations of surgical specimens obtained from all three operations indicated ovarian endometriosis.

Three years prior to this visit, she experienced progressive pelvic pain and she also noticed a growing mass at the right labia majora. She underwent total abdominal hysterectomy (TAH) with bilateral salpingooophorectomy (BSO) and excision of a 3.7 × 2.5 cm labial mass. Pathological examination revealed adenomyosis and multiple leiomyomas in the uterus as well as endometriotic cysts in both ovaries. The labial mass contained focal atypical endometriosis on a background of benign endometriosis (Figures 1 and 2). The patient had an uneventful recovery. However, she did not return to follow-up after this operation. She had no history of hormonal replacement therapy (HRT).

One month before this visit, she had undergone an incision biopsy of her labial mass at the provincial hospital, and the pathological report indicted only apocrine hidrocystoma. Nevertheless, the mass had increased in the size with accompanying progressive pain.

Upon presentation at our hospital, there was a 7x4-cm hard mass at the right labia majora extending to the right groin area. The mass seemed to be in continuity with the pubic symphysis that would require pubic bone excision and reconstruction with flap surgery to achieve complete resection. However, the patient refused such extensive surgery. Based on the previous pathological diagnosis of endometriosis of the vulva in this patient, she was then initially treated with two doses of GnRH agonist followed by one 150 mg dose of depot medroxyprogesterone acetate. These medications were administered with the aim of shrinking the bulk of the mass. However, the mass developed into an ulcer and rapidly increased in size (Figure 3). A second biopsy of the mass was then performed. The pathologic examination showed a papillary growth structure lined by round tumor cells with clear cytoplasm and pleomorphic nucleoli (Figure 4). Figure 5 shows residual atypical endometriosis that had merged with the tumor. The patient’s tumor exhibited focal cytoplasmic staining for napsin A. A diagnosis of clear cell adenocarcinoma of the vulva with coexisting atypical endometriosis was made based on these pathological findings.

Computed tomography of the abdominopelvic region showed an ulcerative mass at the right labia majora and nodal metastasis at the bilateral external iliac and superficial inguinal regions that varied in size from 2.0 to 3.5 cm. Other CT findings were unremarkable.

As this case was considered inoperable, systemic chemotherapy consisting of paclitaxel and carboplatin was administered. The growth of the tumors stabilized during the first two cycles of chemotherapy but rapidly progressed thereafter. Palliative treatment under multidisciplinary care was subsequently initiated. Pelvic radiation was administered to slow down the progression of disease and to alleviate pelvic pain. At 17 months after her initial presentation, the patient passed away due to the progression of the disease and severe sepsis.

3. Discussion

We report a case of vulvar clear cell carcinoma in a 46-year-old nulliparous woman who presented with a four-month history of a lump and pain in the right side of her groin and labia majora. Clear cell carcinoma of the vulva is a rare phenomenon and the most likely mechanism in this
case is malignant transformation of residual foci of atypical endometriosis within the vulva.

Although the pathogenesis of malignant changes in endometriosis remains unclear, hyperestrogenism has been proposed as one of the potential risk factors based on the fact that there are some reported cases in which endometriosis-associated adenocarcinoma developed in the large bowel, bowel mesentry, peritoneum, and vagina during estrogen replacement therapy after TAH with BSO [5–10]. The duration of unopposed estrogen therapy in these reports varied from 22 months to 17 years [5–10]. Interestingly, the pathology in these cases was endometrioid adenocarcinoma [5–10]. However, there is currently no evidence of an association between hyperestrogenism and the occurrence of endometriosis-associated clear cell adenocarcinoma. We believe that the malignant transformation of endometriosis may progress along one of two possible pathways. As endometriosis is an ectopic endometrium, hyperestrogenism may stimulate the transformation of endometriosis into atypical hyperplasia and endometrioid adenocarcinoma, similar to the process by which endometrioid adenocarcinoma has been found to develop in the endometrium [11]. The other possibility is that epithelial atypia arises in an endometriotic lesion and then evolves into clear cell carcinoma, similar to the development of clear cell carcinoma of the ovary [12, 13]. In our patient, pathological examination of the vulvar specimen obtained from her previous operation revealed foci of atypical endometriosis. There was also a tiny cyst merged with clear cell carcinoma, which was suggestive of atypical endometriosis in the vulvar incision biopsy specimen. In addition, our patient had no history of HRT after TAH with BSO.

Currently, the research is inconclusive with regard to the mechanisms that lead to the development of extrapelvic lesions. Extrapelvic endometriosis can occur via iatrogenic seeding of endometrial tissue at surgical sites during labor or an operation in which the endometrial cavity entered such as cesarean section or myomectomy. This accounts for the presence of endometriosis in previous episiotomy sites and abdominal wall scars from cesarean sections. Other explanations for the spread of endometrial tissue to the outside of the pelvis include (i) the transportation of viable endometrial tissue in circulating fluid within the abdominal cavity, (ii) lymphatic or hematogenous dissemination, and (iii) the direct extension from pelvic endometriosis to extrapelvic areas [1].

In our patient, the lesion involved the right side of groin and labia majora. The occurrence of endometriosis in the vulva in our patient, which subsequently transformed to clear cell carcinoma, may have extended from the pelvis via the round ligament. Though extremely rare, the occurrence of endometriosis in the extrapelvic portion of the round ligament has been reported, and it involves the right side in more than 90% of cases [14–17]. One possible explanation for this rare clinical presentation is the presence of atypical lymphatic flows from the peritoneal cavity and pelvis to the right groin or nonobliteration of the parietal peritoneum accompanying the round ligament in the canal of Nuck, thereby enabling the viable endometrial tissue in the peritoneal fluid to deposit along the round ligament [18].
Due to the rarity of endometriosis-associated cancers, the optimal treatment modalities in these cases are not yet known. Complete surgical removal remains the most common treatment in cases of malignant transformation of endometriosis. Neoadjuvant chemotherapy may allow for a complete resection to be performed in some cases [19]. In cases with later presentation, adjuvant platinum-based chemotherapy following tumor debulking is commonly prescribed to minimize the risk of recurrence. However, the prognosis of patients with advanced endometriosis-associated cancer is generally poor because of the intrinsic chemoresistance-related gene of this cancer [20]. In our patient, surgical excision was not technically possible due to the disease being in its advanced stages. A systemic chemotherapy consisting of paclitaxel and carboplatin was commonly prescribed to minimize the risk of recurrence. How- ever, the prognosis of patients with advanced endometriosis-related gene of this cancer [20]. In ever, the prognosis of patients with advanced endometriosis is generally poor because of the intrinsic chemoresistance-related gene of this cancer [20]. In our patient, surgical excision was not technically possible due to the disease being in its advanced stages. A systemic chemotherapy consisting of paclitaxel and carboplatin administered as neoadjuvant treatment was not effective. The time from presentation until death was 17 months.

4. Conclusion

Clear cell adenocarcinoma of the vulva is a rare phenomenon and the most likely mechanism in this case was malignant transformation of residual foci of atypical endometriosis within the vulva. Our report confirms the relatively poor prognosis of this type of tumor, particularly in cases of later presentation.

Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Acknowledgments

The authors are grateful to Dylan Southard for his assistance in editing this manuscript.

References

[1] N. Machairiotis, A. Stylianaki, G. Dryllis et al., “Extrapelvic endometriosis: a rare entity or an under diagnosed condition?” Diagnostic Pathology, vol. 8, no. 1, article 194, 2013.

[2] M. Matalliotakis, G. N. Goulielmos, I. Kalogiannidis, G. Koumantakis, I. Matalliotakis, and A. Arici, “Extra pelvic endometriosis: Retrospective analysis on 200 cases in two different countries,” European Journal of Obstetrics & Gynecology and Reproductive Biology, vol. 217, pp. 34–37, 2017.

[3] R. C. Stern, R. Dash, R. C. Bentley, M. J. Snyder, A. F. Haney, and S. J. Robboy, “Malignancy in endometriosis: frequency and comparison of ovarian and extravarian types,” International Journal of Gynecological Pathology, vol. 20, no. 2, pp. 133–139, 2001.

[4] R. J. Kurman and I.-M. Shih, “The dualistic model of ovarian carcinogenesis revisited, revised, and expanded,” The American Journal of Pathology, vol. 186, no. 4, pp. 733–747, 2016.

[5] M. A. E. Abu, P. Sinha, L. Totoe, and G. McCune, “Endometrial cancer thirteen years after total abdominal hysterectomy and bilateral salpingo-oophorectomy and hormone replacement therapy: A case report,” European Journal of Gynaecological Oncology, vol. 18, no. 6, pp. 482–483, 1997.

[6] G. Debus and I. Schuhmacher, “Endometrial adenocarcinoma arising during estrogenic treatment 17 years after total abdominal hysterectomy and bilateral salpingo-oophorectomy: A case report,” Acta Obstetricia et Gynecologica Scandinavica, vol. 80, no. 6, pp. 589-590, 2001.

[7] K. D. Jones, E. Owen, A. Berresford, and C. Sutton, “Endometrial adenocarcinoma arising from endometriosis of the rectosigmoid colon,” Gynecologic Oncology, vol. 86, no. 2, pp. 220–222, 2002.

[8] S. Kawate, I. Takeyoshi, H. Ikota, Y. Numaga, Y. Sunose, and Y. Morishita, “Endometrioid adenocarcinoma arising from endometriosis of the mesentarium of the sigmoid colon,” Japanese Journal of Clinical Oncology, vol. 35, no. 3, pp. 154–157, 2005.

[9] S. Nomura, T. Suganuma, T. Suzuki et al., “Endometrioid adenocarcinoma arising from endometriosis during 2 years of estrogen replacement therapy after total hysterectomy and bilateral salpingo-oophorectomy,” Acta Obstetricia et Gynecologica Scandinavica, vol. 85, no. 8, pp. 1019–1021, 2006.

[10] A. Al-Talib, L. Gilbert, and J. Arseneau, “Endometrioid adenocarcinoma 13 years after total abdominal hysterectomy and bilateral salpingo-oophorectomy,” Saudi Medical Journal, vol. 29, no. 7, pp. 1044–1047, 2008.

[11] R. Murali, R. A. Soslow, and B. Weigelt, “Classification of endometrial carcinoma: More than two types,” The Lancet Oncology, vol. 15, no. 7, pp. e268–e278, 2014.

[12] C. Zhao, L. S.-F. Wu, and R. Barner, “Pathogenesis of ovarian clear cell adenofibroma, atypical proliferative (borderline) tumor, and carcinoma: clinicopathologic features of tumors with endometriosis or adenofibromatous components support two related pathways of tumor development,” Journal of Cancer, vol. 2, no. 1, pp. 94–106, 2011.

[13] P. Kleebkaow, A. Aue-aungkul, A. Temtanakitpaisan, and C. Kietpeerakool, “Borderline Clear Cell Adenofibroma of the Ovary,” Case Reports in Pathology, vol. 2017, Article ID 3860107, 4 pages, 2017.

[14] Y. Hagiwara, M. Hatori, T. Moriya et al., “Inguinal endometriosis attaching to the round ligament,” Journal of Medical Imaging and Radiation Oncology, vol. 51, no. 1, pp. 91–94, 2007.

[15] S. Licheri, G. Pisano, E. Erdas et al., “Endometriosis of the round ligament: Description of a clinical case and review of the literature,” Hernia, vol. 9, no. 3, pp. 294–297, 2005.

[16] R. Prabhu, S. Krishna, R. Shenoy, and S. Thangavelu, “Endometriosis of extra-pelvic round ligament, a diagnostic dilemma for physicians,” BMJ Case Reports, 2013.

[17] F. Abu Saadeh, N. A. Wahab, and N. Gleeson, “An unusual presentation of endometriosis,” BMJ Case Reports, 2014.

[18] G. B. Candiian, P. Vercellini, L. Fedele, N. Vendola, S. Carinelli, and V. Scaglione, “Inguinal endometriosis: pathogenetic and clinical implications,” Obstetrics & Gynecology, vol. 78, no. 2, pp. 191–194, 1991.

[19] R. Fruscio, F. Padula, E. Mancini, A. Pellegrino, and M. De Nictolis, “Malignant transformation of vaginal endometriosis
treated with neoadjuvant chemotherapy and surgery,” *Journal of Obstetrics and Gynaecology Research*, vol. 34, no. 1, pp. 706–708, 2008.

[20] D. Pectasides, E. Pectasides, A. Psyrri, and T. Economopoulos, “Treatment issues in clear cell carcinoma of the ovary: A different entity?” *The Oncologist*, vol. 11, no. 10, pp. 1089–1094, 2006.